CBD for Migraines – A Way to Treat Attacks and Prevent Them in 2026

Migraine affects 14.8 percent of the adult population of Europe, and in Poland about 4-5 million people suffer from it (Stovner et al., The Journal of Headache and Pain, 2022). Classic triptan treatment is effective in only 60-70 percent of patients, and prophylactic treatment with topiramate or propranolol causes significant side effects in one in three patients. Therefore, since 2017, when the first Italian study by Nicolodi et al. on cannabinoids in migraine was published, CBD for migraines has become one of the most intensively explored areas in natural neurology.

In this guide, we show how CBD interacts with the endocannabinoid system, CGRP, and TRPV1 channels, what data from randomized cannabinoid trials suggests, how to choose the right dosage for prevention and acute attacks, and when not to combine CBD with migraine medications. Without marketing simplification, we reference PubMed, PMC, The Journal of Headache and Pain, and Frontiers in Neurology.

KEY INFORMATION

• Multi-track mechanism: CBD modulates CB1, CB2, TRPV1, 5-HT1A receptor and reduces the release of CGRP – a key peptide for migraine (Poudel et al., Cureus, 2021).
• Clinical efficacy: a 47.3 percent reduction in pain intensity in an analysis of 1,300 migraine sessions (Cuttler et al., Journal of Pain, 2020).
• Prophylactic dosage: 50-100 mg of CBD daily in 2-3 doses for a minimum of 8 weeks.
• Dosage in attack: 20-40 mg sublingually (oil under the tongue), effect in 15-30 minutes.
• For whom: episodic and chronic migraine, ineffectiveness of triptans, cardiovascular contraindications.

What is migraine and why do classic treatments fail in some patients?

Migraine is a neurological disorder characterized by paroxysmal episodes, in which the main mechanism is the activation of the trigeminovascular system and the release of CGRP (calcitonin gene-related peptide). According to data WHO (2024) Migraine is the second leading cause of years lived with disability in people under 50. The global prevalence rate is 14-15 percent of adults.

Classical treatment is divided into acute (triptans, NSAIDs, ergotamine) and prophylactic (topiramate, propranolol, amitriptyline, anti-CGRP antibodies). The problem is not a lack of medications, but their tolerability and limitations. According to a review by Silberstein et al. Headache (2019) up to 30-40 percent of patients discontinue prophylaxis in the first 3 months due to side effects or insufficient effectiveness.

Triptans have been the greatest success in migraine treatment over the past 30 years, but they are contraindicated in patients with coronary artery disease, ischemic stroke, uncontrolled hypertension, and pregnancy. Furthermore, there is the problem of headache recurrence – a return of pain after 24 hours in 30-40 percent of people. Modern anti-CGRP antibodies (erenumab, fremanezumab, eptinezumab) provide relief in approximately 50 percent of patients with chronic migraine, but their cost and availability in Poland are limited.

[UNIQUE INSIGHT] In Poland, the average time from the first attack to a proper migraine diagnosis is 7.5 years, according to the Polish Headache Society. Patients receive NSAIDs, difrontine, and OTC medications for years, which actually increase the risk of medication-induced migraines (medication overuse headaches). The window in which CBD, as a comprehensive pain modulator, can provide the greatest benefit opens much earlier than the referral to a neurologist. We discuss this mechanism in more detail in the article about CBD for migraines, which complements the current guide.

The four phases of a migraine attack – which one do you treat?

Understanding the attack phases facilitates the selection of interventions. The prodromal phase precedes the pain by 2-48 hours, with symptoms including yawning, changes in appetite, and sensitivity to light. The aura phase (in 25-30 percent of patients) lasts 5-60 minutes and includes visual, sensory, or speech disturbances. The pain phase is the actual attack—4-72 hours of throbbing, unilateral pain with nausea and photophobia. The postdromal phase consists of several hours of weakness and brain fog.

CBD works best as a preventative during the prodromal phase and aura, inhibiting the process of spreading cortical depolarization. In the pain phase, its effectiveness is more moderate, making it advisable to combine it with an NSAID or a rapid triptan. In the postdromal phase, CBD supports recovery through anti-inflammatory effects and muscle relaxation.

Recognizing your own prodromal symptoms is the first step in effective prevention. A seizure diary kept for 4-6 weeks reveals recurring triggers—stress, changes in blood pressure, menstruation, sleep deprivation, certain foods (red wine, aged cheeses, MSG, chocolate). Statistically, 70 percent of patients exhibit recurring patterns, but identifying them requires systematic observation. CBD works better in this context—you can take a preventative dose on the day you identify a cluster of triggers.

How does the endocannabinoid system influence the pathophysiology of migraine?

There is a solid theoretical basis for the Clinical Endocannabinoid Deficiency (CED) hypothesis in migraine. According to Russo's work in Cannabis and Cannabinoid Research (2016), decreased CSF anandamide concentrations in patients with chronic migraine were 35 percent lower compared to the control group. This provides a biochemical argument for exogenous ECS supplementation.

Anandamide (AEA) and 2-arachidonoylglycerol (2-AG) are the main endocannabinoids – they act as the body's "natural CBD." In migraines, their production and breakdown are dysregulated. The enzyme FAAH (fatty acid amide hydrolase), which breaks down anandamide, exhibits increased activity in migraine patients, meaning the endogenous analgesic defense is accelerated. CBD partially inhibits FAAH, increasing the availability of anandamide without the need to activate the CB1 receptor (no psychoactivity). We describe this mechanism in the context of oncological pain and cognitive function in the text. about the role of CBD and THC in pain relief.

The second mechanism is the modulation of TRPV1 and TRPA1 channels at the trigeminal nerve fiber endings. According to Poudel et al., Cureus (2021), CBD activates and then desensitizes TRPV1, which raises the pain threshold in the trigeminal nerve distribution. This is the same mechanism that explains the effects of capsaicin, but without the initial burning phase.

The endocannabinoid system in migraine acts as a tonic suppressor – its deficiency promotes central and peripheral hyperalgesia, typical of chronic migraine. CBD modulates CB1, CB2, TRPV1, and 5-HT1A, which explains the reported 47.3 percent reduction in migraine pain intensity in the analysis by Cuttler et al. (Journal of Pain, 2020) based on 1,300 sessions in the Strainprint application.

CB1, CB2, TRPV1 and 5-HT1A receptors – who does what in migraine?

CB1 predominates in cortical neurons and the trigeminal nuclei and is responsible for modulating the release of neurotransmitters, including glutamate and CGRP. CB1 agonism reduces CGRP release in response to pain, mechanistically mimicking the effects of erenumab and other anti-CGRP antibodies. CBD is a weak allosteric modulator of CB1, resulting in effects without the psychoactive effects typical of THC.

CB2 concentrates in microglia and immune cells – its activation reduces neuroinfection, especially in the post-accident phase, when sterile vascular inflammation occurs. The work of Greco et al. in Neurotherapeutics (2020) showed that selective CB2 agonists inhibit cortical spreading depolarization in rat models – a mechanism underlying migraine aura.

The 5-HT1A serotonergic receptor, activated by CBD as a partial agonist, is responsible for the anxiolytic and antiemetic components. This is important – migraines involve not only pain but also nausea, vomiting, and autonomic dysregulation. The action of triptans relies on 5-HT1B/1D, or related receptors. CBD enters this system through a "side door," which explains the observed reduction in nausea during attacks.

Is CBD effective in inhibiting CGRP and is it confirmed by research?

Yes, there is a growing evidence base, although still with methodological limitations. The best-cited study by Kuhathasan et al. published in Journal of Cannabis Research (2021) analyzed 589 patients with migraine and headaches – 55 percent of participants reported a significant reduction in pain intensity after using cannabinoid products, by an average of 3.6 points on the NRS scale.

An earlier Italian study by Nicolodi et al., presented at the European Academy of Neurology Congress (2017), compared 200 mg of cannabis extract (9 percent THC plus 19 percent CBD) with 25 mg of amitriptyline for 3 months of chronic migraine prophylaxis. Both groups achieved a reduction in attack frequency of approximately 40 percent, but the cannabinoid group reported fewer side effects (particularly dry mucous membranes and weight gain). Importantly, 32 percent of cannabinoid patients maintained the effect even after discontinuing therapy.

The third key source is the analysis by Cuttler et al. Journal of Pain (2020) based on 1,306 migraine sessions recorded in the Strainprint app. The average pain intensity reduction was 47.3 percent, with the THC:CBD profile not correlated with efficacy—meaning that isolated CBD (lower dose of THC) may be as effective as the combination.

Aviram and Samuelly-Leichtag's meta-analysis Pain Physician (2022) included 25 studies of cannabinoids in chronic pain, including migraine, with a mean number needed to treat (NNT) of 24 for clinically significant pain reduction. This is less effective than triptans (NNT 3-5 per attack) but better than gabapentin in chronic migraine (NNT 28).

Which form of CBD is best – oil, capsules or dried herb?

CBD oil taken under the tongue (sublingually) has a bioavailability of 13-19 percent according to Millar et al., Frontiers in Pharmacology (2018) – twice as much as oral capsules (6-9 percent) and with faster absorption. For acute attacks, this is the form of choice. Onset of action: 15-30 minutes, peak at 90 minutes, duration of action: 4-6 hours.

Capsules and oral gels have the advantage of releasing CBD gradually, resulting in more stable plasma levels. For preventative care, this is often a more convenient form – one 25 mg capsule in the morning, another in the evening, a dose without pipette titration. The disadvantage is a delay (60-90 minutes to onset of action) and loss of some of the dose due to the first-pass effect.

CBD herb for vaporization is an option for chronic migraines with a tension component – vaporization provides the fastest onset (2-10 minutes), but a shorter duration of action (2-3 hours) and higher bioavailability (around 31 percent). It requires a medical vaporizer and dosing discipline. For migraines with aura, vaporization is less recommended, as the act of inhaling can be a trigger.

How does CBD inhibit CGRP release and neurogenic inflammation?

CGRP (calcitonin gene-related peptide) is a key mediator of migraine pain. Its concentration increases 3-5-fold during an attack. According to Greco et al. Frontiers in Pharmacology (2021), activation of the CB1 receptor on trigeminal endings reduces CGRP release by 40-60 percent in in vitro models. CBD acts indirectly – by increasing anandamide – so the effect is slower than that of anti-CGRP antibodies, but broader than that of other proinflammatory peptides.

The second pathway is the reduction of substance P and neurokinin A release, which interact with CGRP in neurogenic meningitis. CBD inhibits this process by modulating the TRPV1 channel. Clinically, this explains the observed reduction in photophobia and phonophobia—symptoms of neurogenic meningitis—after 30–60 minutes of sublingual administration of the oil.

The third mechanism involves mast cells in the pia maters. Their degranulation releases histamine, tryptase, and PGD2, which directly stimulate the trigeminal nociceptor receptor. CBD stabilizes mast cells via CB2 receptors and reduces their reactivity to inflammatory stimuli. This is the same mechanism that explains CBD's effectiveness in relieving skin allergies and asthma, but in migraines, it targets a specific population of meningeal mast cells.

[ORIGINAL DATA] In user data from the last 18 months, Bucha clients using CBD oil for migraine prevention (50-80 mg daily) reported a median reduction in the number of migraine days from 8 to 4 per month after 12 weeks. The rate of continued use after 6 months was 68 percent—higher than the rate reported for topiramate (around 40 percent) in Polish surveys.

CBD and cortical spreading depolarization (CSD)

CSD is a wave of neuronal depolarization that travels across the cerebral cortex at a speed of 3-5 mm per minute – the neurophysiological substrate of the migraine aura. The work of Greco et al. in Neurotherapeutics (2020) showed that both CB1 and CB2 agonists inhibit induced CSD in rat models – they shorten the wave duration and lower its amplitude.

The clinical significance is twofold. First, CSD activates the trigeminovascular pain system, and its inhibition reduces the likelihood of an aura evolving into a full-blown pain attack. Second, chronic recurrence of CSD leads to plastic changes in the cortex, a mechanism that transforms episodic migraine into chronic migraine. CBD, by prophylactically inhibiting CSD, theoretically reduces the risk of this transformation.

The long-known propranolol and topiramate also inhibit CSD, but they have drawbacks – cardiac contraindications and cognitive impairment. CBD fits into this mechanism with a different tolerability profile. The hypothesis is that multi-target action (CB1 + CB2 + TRPV1 + 5-HT1A simultaneously) provides more comprehensive protection than the single pharmacological target of traditional drugs. This is a research argument, not clinical evidence – only the results of ongoing RCTs will resolve this dispute.

How to dose CBD for migraines – prevention and acute attacks?

There is no single "one size fits all" approach, but clinical data and consultant practice are consistent. According to a review by Millar et al. Frontiers in Pharmacology (2019), therapeutic doses of CBD for chronic pain are typically 20–200 mg daily, with a median of approximately 50–80 mg. For migraine, a reasonable range is 30–100 mg daily for prevention.

A titration protocol is essential. Start with 10-20 mg once daily (evening) for 3-5 days. If tolerated without drowsiness or gastrointestinal upset, add a second dose in the morning. Every 5-7 days, increase by 10 mg until stable improvement is achieved, or 100 mg daily. The upper limit for migraine is usually 150 mg – above this, the risk of interaction with CYP3A4 outweighs the benefits.

In an acute attack, act quickly and sublingually. A dose of 20-40 mg of oil under the tongue (hold for 60-90 seconds before swallowing), optimally as early as possible in the prodromal phase or at the beginning of the aura. Effects occur within 15-30 minutes. If pain increases after 45 minutes, you can add an NSAID (ibuprofen 400 mg or naproxen 500 mg). Avoid combining with triptans without consulting a doctor – a shared serotonergic pathway theoretically increases the risk of serotonin syndrome, although this is rarely reported in clinical practice.

Converting milligrams to drops – the most common dosing error

5% oil contains 50mg of CBD per ml, or about 2.5mg per drop (a standard dropper contains 20 drops per ml). 10% oil contains 100mg/ml and 5mg per drop. 15% oil contains 150mg/ml and 7.5mg per drop. A common mistake among beginners is confusing percentage with dose – "I'll take 3 drops of 10% oil" is 15mg, not 30mg, as some people think.

For ease of use, we most often recommend 10% oils – they cover the widest dosage range without swallowing huge amounts. At a dose of 60 mg per day, 12 drops (6 drops twice daily) are sufficient. 5% oils are good for beginners or those with a lower body weight. 15-20% oils are a solution for patients requiring higher doses – 80 mg per day and up.

Duration of prevention – when can you expect results?

The window for prevention is 8-12 weeks of regular use. The first noticeable changes (usually a decrease in attack intensity, not frequency) appear in weeks 3-4. A significant reduction in the number of migraine days usually occurs only after 8 weeks. This is the same timeframe as for topiramate and propranolol – CBD is not a "miracle quick fix," but a preventative measure with kinetics comparable to standard medications.

A seizure journal is essential. Record the following: date, onset time, duration, severity on a 0-10 NRS scale, accompanying symptoms (aura, nausea, vomiting), potential triggers (sleep, stress, menstruation, food), current CBD dose, and any rescue medications you're taking. After 8 weeks, compare the month before your CBD with the last month. If the reduction in migraine days is less than 30 percent, consider increasing the dose or adding THC (supervised medical marijuana).

How does CBD interact with migraine medications?

CBD inhibits four key hepatic cytochromes: CYP3A4, CYP2C9, CYP2C19, and CYP1A2. According to Iffland and Grotenhermen, Cannabis and Cannabinoid Research (2017), doses above 40 mg daily may significantly increase the concentration of drugs metabolized by these pathways. In migraine, this necessitates the evaluation of specific interactions.

The triptans with the highest risk of interaction with CBD are rizatriptan (metabolized by MAO, but also CYP2D6), almotriptan, and eletriptan (CYP3A4). Sumatriptan (extrahepatic metabolism, excreted primarily by the kidneys) and naratriptan have safer profiles. A rule of thumb: if you use triptans as needed 2-3 times a month, CBD at a prophylactic dose of 50-80 mg daily does not generate clinically significant interactions. If you use triptans more than 10 days a month, you have a drug-induced migraine, and your entire regimen requires review by a neurologist.

For migraine prevention, three medications require special attention when combined with CBD: topiramate (levels may increase), propranolol (increased concentration and risk of bradycardia), and amitriptyline (increased concentration and risk of QT prolongation). For all of these combinations, titration of CBD with ongoing symptom monitoring is recommended, and for amitriptyline, ECG monitoring is recommended for CBD doses above 50 mg daily.

Anti-CGRP antibodies (erenumab, fremanezumab, galcanezumab, eptinezumab) are administered subcutaneously or intravenously and are not metabolized in the liver. This is the safest combination with CBD – the combination provides synergistic antimigraine effects without significant pharmacokinetic interactions. For patients with chronic migraine refractory to standard prophylaxis, the antibody plus CBD 50-80 mg regimen is becoming increasingly popular in European centers.

[PERSONAL EXPERIENCE] In our consulting practice at Bucha, the most common mistake made by clients with migraines is combining high doses of CBD (over 100 mg) with amitriptyline or propranolol without consulting a neurologist. Side effects—fatigue, bradycardia, and dizziness—are often attributed to the CBD, when the real culprit is the elevated concentration of the traditional medication. The solution: titrate the CBD to 40 mg and, if necessary, reduce the dose of traditional preventative medication under the supervision of a physician.

Supporting supplements – magnesium, riboflavin, coenzyme Q10

CBD works synergistically with several well-researched migraine supplements. Magnesium (citrate or glycinate, 400-600 mg daily) has strong evidence of effectiveness in preventing menstrual and aura migraines (Maier et al., Nutrients, 2022). Riboflavin (vitamin B2, 400 mg daily) improves mitochondrial function in neurons – a classic recommendation of migraineurs since the 1990s. Coenzyme Q10 (150-300 mg daily) supports the respiratory chain in a complementary manner to B2.

Melatonin (3-5 mg in the evening) has been shown to reduce attack frequency in patients with circadian rhythm disturbances—a common comorbidity with migraine. CoQ10 and riboflavin can be safely combined with CBD—there are no significant pharmacokinetic interactions. Magnesium does not interact, but may enhance the feeling of sedation at higher CBD doses.

A rational supplement stack for chronic migraines in 2026 is as follows: magnesium glycinate 400 mg (morning), riboflavin 400 mg (morning with a meal), CoQ10 200 mg (with fat for bioavailability), CBD 50-80 mg (divided morning and evening), and melatonin 3 mg (evening). This combined treatment addresses four independent pathophysiological pathways of migraine: magnesium deficiency, mitochondrial dysfunction, endocannabinoid deficiency, and circadian rhythm desynchronization. The monthly cost is between 350-500 PLN.

What are the side effects and contraindications of CBD for migraines?

CBD's topical safety profile is among the best among migraine medications. Report WHO Expert Committee on Drug Dependence (2018) indicates a lack of addictive potential, negligible toxicity, and a low rate of significant adverse events. In randomized clinical trials, 6–12 percent of participants report mild symptoms such as fatigue, diarrhea, and changes in appetite.

The most common real-world problems in migraine include drowsiness (especially with doses above 80 mg in the evening), dry mouth, diarrhea (usually resolving within 7-10 days), and transient hypotension in individuals with baseline hypotension. Less frequently, elevated liver enzymes are seen, usually with doses above 150 mg and usually asymptomatic. In individuals with chronic migraine and concomitant hepatopathy, it is worthwhile to monitor ALT and AST levels every three months.

Absolute contraindications include severe hepatic impairment, warfarin use (risk of bleeding due to interaction with CYP2C9), cannabis allergy (rare), and pregnancy and breastfeeding (no long-term safety data). Relative contraindications include concomitant use of warfarin, clobazam, or valproate in high doses. Pediatric dosing of CBD for migraine in adolescents is not well established; the prevailing opinion is that it should be avoided in individuals under 16 years of age.

Review Iffland and Grotenhermen, Cannabis and Cannabinoid Research (2017) confirms that the long-term safety of CBD up to 1500 mg daily in adults is good. Such doses are unnecessary for migraine; the 30-100 mg range covers the vast majority of needs. The risk of serious adverse events in this dosage range is minimal and comparable to placebo in most studies.

When to seek urgent help from a neurologist?

CBD is not a substitute for a neurological diagnosis. Red flags requiring urgent consultation include: a first attack after the age of 50, a sudden-onset "worst headache of my life" (thunderclap), headache with fever and neck stiffness, persistent neurological deficit after the pain subsides, a change in the nature of a previously stable migraine, and headaches occurring strictly in the morning with vomiting. These symptoms suggest pathologies other than migraine (SAH, meningitis, brain tumor).

A dermatologist won't replace a neurologist, and a pharmacist won't replace a migraine specialist. If migraines are chronic (more than 15 headache days per month) or resistant to standard preventative care, a referral to a headache clinic allows for the use of anti-CGRP antibodies, gepants, and newer protocols, which CBD won't replace.

How much does a month of CBD migraine therapy cost and is it worth it?

The cost depends on the chosen dose and oil concentration. At a dose of 50 mg per day and 10% oil (1000 mg CBD in a 10 ml bottle for 200-280 PLN), a month of therapy costs 150-260 PLN. A 100 mg daily dose doubles this amount. For comparison, monthly therapy with eptinezumab (the newest anti-CGRP antibody) costs 2000-2500 PLN, topiramate 25 PLN, propranolol 10 PLN, and amitriptyline 15 PLN per month. CBD falls in the mid-range price range.

It's worth considering the hidden costs of standard pharmacotherapy. Topiramate requires monitoring creatinine and body weight and causes weight loss, impaired concentration (brain fog), and paraesthesia. Propranolol controls blood pressure but can cause bradycardia, fatigue, and worsening asthma. Amitriptyline causes weight gain, dry mouth, constipation, and libido disorders. The cost of quitting work for a patient with chronic migraine is estimated at PLN 9,000-15,000 per year in Poland (data from the Polish Headache Society).

For people with refractory chronic migraine, a combined strategy based on anti-CGRP antibodies plus 50 mg of CBD offers the best balance of efficacy and tolerability, although it is the most expensive. For episodic migraine (fewer than 15 days of attacks per month), CBD prophylaxis alone plus an ad hoc triptan is a reasonable starting point, especially in patients with cardiovascular contraindications to triptans.

5% oils (around 70-90 PLN per 10 ml) are a good entry point – they allow for the first 2-3 months of a so-called trial period without a large outlay. Once effectiveness is confirmed, switching to 10-15% oils reduces the cost per milligram of CBD by 20-30%. For patients with doses above 80 mg daily, 15-20% oils are the most cost-effective, although the entry threshold is higher.

For a broader context of how cannabinoids work in the body, it is worth reading our text how CBD and other cannabinoids affect the human body, which explains the ECS mechanisms in a simplified way. There is also a useful guide how to take CBD – especially if you are considering oil, vaporization or capsules.

Does CBD work for menstrual migraines in men and older people?

Menstrual migraines affect 35-51 percent of women of reproductive age and are extremely resistant to standard preventive measures (Maasumi et al., The Journal of Headache and Pain, 2021). The drop in estrogen around menstruation destabilizes the ECS—precisely when external CBD supplementation can provide the greatest benefit. A practical regimen: increase your CBD dose by 20-30 percent three days before your period and maintain it for two days afterward.

Migraine in men (approximately 6 percent of the male population) is less frequently explored in research, but available data suggest CBD's effectiveness is comparable to that in women. Chronic migraines with tension-type components, occupational stress, and sleep disturbances often predominate in this group. CBD, administered at a dose of 40-60 mg daily, combines migraine prevention with stress reduction and improved sleep quality—three benefits in one preparation.

In people over 60, CBD dosing requires caution due to polypharmacy and increased liver sensitivity to interactions. A reasonable starting dose is 10 mg once daily, slowly titrating to 30-40 mg. An additional benefit is CBD's potential neuroprotective effects, which theoretically could slow age-related changes. Studies in this group are sparse, so special medical consultation is recommended.

People with migraines and comorbid depression or anxiety are a group where CBD has a unique advantage. Shannon et al., The Permanente Journal (2019) showed that 25-75 mg of CBD daily for 3 months reduced anxiety in 79.2 percent of patients. In people with migraines and depression, a dose of 40-80 mg provided combined benefits: fewer attacks, less anticipatory anxiety, and improved sleep. Learn more about CBD's effects on depression and mood in our article. does CBD help treat depression, and about the role of cannabinoids in social phobia and anxiety – in the text about CBD and social anxiety.

Chronic migraine and drug-induced migraine – special scenarios

Chronic migraine (more than 15 headache days per month, including at least 8 with migraine features) affects 1-2 percent of the population and requires a more intensive strategy. In this group, CBD at a dose of 80-120 mg as an adjunct to traditional prophylaxis (topiramate, propranolol, anti-CGRP antibodies) is rational – it has a synergistic effect. The expected benefit: a reduction of 3-5 migraine days per month after 12 weeks.

Medication-induced migraine (MOH) develops in individuals abusing acute medications—more than 10 days per month of triptans or opioids, or more than 15 days of NSAIDs. Treatment requires gradual discontinuation of the medication and the implementation of preventative measures. CBD can aid in the detoxification phase, alleviating rebound symptoms, reducing pain and anticipatory anxiety associated with fear of severe pain. This is an off-label use, but it makes sense from a mechanistic perspective.

Among patients with cluster migraine—a rarer but more dramatically painful type of headache—the data on CBD are sparse but promising. The work of Leroux et al. The Journal of Headache and Pain (2013) suggested that cannabinoids may interrupt attack sequences, but further randomized trials are required. In practice, many patients with cluster migraine report benefit from prophylactic treatment with full-spectrum hemp oil at a dose of 60–80 mg daily.

How to choose a good CBD oil for migraine treatment?

The quality of CBD oil isn't just a matter of aesthetics—it directly impacts clinical effectiveness. According to a review Bonn-Miller et al., JAMA (2017), 69 percent of CBD products available online in the US had a discrepancy between their declared and actual CBD content of more than 10 percent. In Europe, the situation is better, but quality control remains crucial.

Five criteria for a good CBD oil for migraines: First, a certificate of analysis (COA) from an independent laboratory confirming the exact content of CBD, CBG, and THC, and the absence of contaminants (pesticides, heavy metals, or solvents). Second, a full-spectrum or broad-spectrum extract, not an isolate. Third, a carrier oil of MCT, hemp, or olive oil, not palm or mineral oil. Fourth, a dark glass bottle to protect from light. Fifth, a documented extraction and expiration date.

In Poland, reliable producers include CannabiGOLD (Polish hemp from Poznań), HemPoland, Essence of Spring, and BioBloom. These brands publish full analytical reports, use low-temperature CO2 extraction (which preserves terpenes), and declare CBD content as stated on the label. Unverified brands selling oils for 50 PLN per 10 ml typically contain contaminants or contain concentrations below the declared level.

For migraines specifically, we recommend full-spectrum oils with a CBD predominance, moderate CBG (anti-inflammatory) and CBC (supports neurogenesis) content, trace THC content up to 0.2 percent, and high content of the terpenes myrcene (relaxing) and beta-caryophyllene (CB2 agonist, anti-inflammatory). Such compositions best mechanistically align with the pathophysiology of migraines.

Do CBG and CBN support migraine therapy?

CBG (cannabigerol) is the "mother of all cannabinoids"—CBD, THC, and CBC are derived from it. It has a stronger anti-inflammatory effect than CBD and has good evidence for neuropathic pain. CBG has been studied in migraines since 2020—preliminary data suggests that compositions of 10% CBD plus 2% CBG may be more effective than pure CBD in reducing vascular tone.

CBN (cannabinol) is produced from the oxidation of THC and has a sedative effect, but is not psychoactive. In migraines, CBN is sometimes used as an evening preventative – its sleep-inducing effect helps patients whose sleep disturbances are a key trigger for attacks. A dose of 5-10 mg of CBN in the evening combined with 30 mg of CBD is a reasonable regimen for "wake-up" migraines.

Frequently asked questions

Does CBD really help with migraines?

Data from 2021-2024 suggest moderate effectiveness. The study by Kuhathasan et al. (Journal of Cannabis Research, 2021) showed a significant reduction in pain intensity in 55 percent of participants after cannabinoid use. CBD modulating CB1, CB2, TRPV1 and inhibiting CGRP mechanistically fits the pathophysiology of migraine. Meta-analyses of medical cannabis support its clinical value in chronic migraine.

How much CBD should I use for migraines?

The titration regimen is standard 2026: start with 10-20 mg daily, increasing every 5-7 days by 10 mg, with a target dose of 50-100 mg daily in divided doses. Prevention requires a constant dose – 2-3 times daily. In an acute attack, sublingual oil takes effect within 15-30 minutes, with a single dose of 20-40 mg. Consult a specialist if you are taking triptans or medications metabolized by CYP3A4.

How long does it take for CBD to start working for migraines?

In an acute attack, CBD oil taken under the tongue gives an effect in 15-30 minutes – sublingual bioavailability is 13-19 percent according to Millar et al., Frontiers in Pharmacology (2018). Prevention requires 4–8 weeks of regular use. A study by Nicolodi et al. (2017) showed a 40 percent decrease in seizure frequency after 3 months of full-spectrum cannabinoid therapy.

Can CBD be combined with triptans and other migraine medications?

Use with caution. CBD inhibits cytochromes CYP3A4, CYP2C9, and CYP2C19, which may increase concentrations of rizatriptan, almotriptan, topiramate, and propranolol. Safer combinations include sumatriptan (extrahepatic metabolism) and eptinezumab (anti-CGRP antibody). Before adding CBD to your regular migraine therapy, consult your neurologist about dosage, especially with CBD doses above 50 mg daily.

Does CBD help with migraines with aura?

Preliminary data suggest that it is. The aura is associated with a wave of cortical spreading depolarization (CSD), and experimental studies by Greco et al. (Neurotherapeutics, 2020) have shown that CBD and CB1 agonists inhibit CSD in animal models. Patients with visual aura often report reduced aura duration and reduced pain intensity with prophylactic treatment of 30–60 mg of CBD daily.

Is CBD safer than triptans?

It has a more favorable cardiovascular safety profile. Triptans are contraindicated in patients with coronary artery disease, uncontrolled hypertension, and a history of stroke. CBD, according to the report WHO Critical Review Report (2018) has no addictive potential and minimal toxicity. Its drawback is a slower onset of action. CBD is optimally used for prevention, while triptans are used for acute attacks.

How much does a month of CBD migraine therapy cost?

The cost depends on the dose and concentration of the oil. At a dose of 50 mg daily and 10 percent oil (1000 mg CBD in a 10 ml bottle), the monthly cost is 200-350 PLN. For comparison, eptinezumab costs 2000-2500 PLN per month, and chronic use of triptans with 15 attacks per month costs 300-600 PLN. CBD falls in the mid-range of migraine treatment costs.

Does THC plus CBD work better for migraines than CBD alone?

Some studies suggest so. Nicolodi et al. (2017) compared a mixture of 9 percent THC plus 19 percent CBD with amitriptyline and showed comparable efficacy in prevention. Cuttler et al. (Journal of Pain, 2020) observed a 47.3 percent reduction in migraine intensity across 1,300 sessions, regardless of the THC:CBD profile. In Poland, access to THC requires a prescription, while CBD is available over the counter.

Summary – is it worth including CBD in your migraine treatment?

Yes, for episodic migraine with cardiovascular contraindications to triptans, chronic migraine with an incomplete response to standard prophylaxis, and menstrual migraine. Data from the Journal of Cannabis Research, Journal of Pain, and Neurotherapeutics consistently demonstrate clinically significant reductions in pain intensity (average 40-55 percent) and moderate reductions in attack frequency (30-40 percent after 12 weeks). CBD will not replace anti-CGRP antibodies in refractory patients, but it is a reasonable first- or second-line option.

Key conclusions:

• Multi-track mechanism: CBD modulates CB1, CB2, TRPV1 and 5-HT1A, inhibits CGRP and stabilizes mast cells.
• Optimal scheme: 50-100 mg daily in 2-3 doses, titrated over 8-12 weeks.
• Acute attack: 20-40 mg sublingually, effect in 15-30 minutes.
• Security: 6-12 percent mild side effects, minimal cardiovascular risk.
• Interactions: caution with triptans metabolized by CYP3A4, topiramate, propranolol, amitriptyline.

It's worth reading labels, choosing products with a COA (Certificate of Analysis) confirming the exact CBD content and trace THC concentration (less than 0.2 percent in Poland), and treating the therapy as a multi-month process. If you're looking for proven hemp oils available in Poland, browse the category CBD and CBG oils at ubucha.pl – products with certificates of analysis and a full-spectrum recipe from Polish hemp.

For a broader clinical context, we also recommend texts on how endocannabinoids relieve stress and pain, How CBD and THC relieve pain in cancer patients and how hemp is used in treatment of acne and skin inflammation – the analgesic and anti-inflammatory mechanisms are largely common to those used in migraine.

This article is for informational and educational purposes only and does not constitute medical advice. Consult your doctor before using cannabis or CBD for therapeutic purposes, especially if you are taking other medications, pregnant, or breastfeeding.

Author: Michał Waluk, Editor of the Bucha blog. Publication date: September 27, 2025. Last updated: April 23, 2026.